Non-invasive Clinical Imaging of Cerebral Metabolism Following Brain Injury Using 13C Magnetic Resonance Spectroscopy.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02745210|
Recruitment Status : Terminated (The acquisition sequence was incompatible with MRI hardware)
First Posted : April 20, 2016
Results First Posted : December 31, 2020
Last Update Posted : December 31, 2020
Despite the decline in fatal traumatic brain injury (TBI) incidence in recent years, TBI morbidity remains a public health challenge and is the leading cause of disability in the United States. Detailed knowledge of the metabolic alterations following TBI will provide a significant advancement to our understanding of the hypometabolic response to TBI, which is key information for the future development and testing of novel therapeutic interventions that by-pass or compensate for the metabolic dysfunction.
The goal of this study is to determine the clinical utility of in vivo 13C MRS to identify specific metabolic alterations following TBI. We hypothesize that following TBI, metabolic pathways are altered causing an incomplete oxidative of glucose in neurons and astrocytes resulting in a decrease in cerebral metabolism.
|Condition or disease||Intervention/treatment||Phase|
|Traumatic Brain Injury||Diagnostic Test: 13C magnetic resonance spectroscopy||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||9 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Non-invasive Clinical Imaging of Cerebral Metabolism Following Brain Injury Using 13C Magnetic Resonance Spectroscopy|
|Actual Study Start Date :||September 2009|
|Actual Primary Completion Date :||February 2019|
|Actual Study Completion Date :||February 2019|
13C Magnetic resonance (MR) spectroscopy.
Diagnostic Test: 13C magnetic resonance spectroscopy
acquisition of 13C MR spectroscopy in the brain
Other Name: 13C MRS
- Detection of 13C Enriched Cerebral Metabolites [ Time Frame: 5 years ]Direct detection, localized in vivo 13C MRS will be used to measure the 13C enrichment of glutamate and glutamine following an infusion of 30% isotopically enriched [1-13C] glucose and [1, 2-13C2] acetate.